Product Information
AMLODIPINE-OLMESARTAN 10-40 MG is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.2987 per EA under NDC 31722044830. Its NADAC has been published 54 times since Sep 24, 2025.
FDA first approved this application on Feb 14, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Amlodipine and Olmesartan Medoxomil market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
10; 40 mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722044830
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA209591FDA Approved
2/14/2025
TE Code
AB
On Market Since
2/14/2025
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-OLMESARTAN 10-40 MG has been published 54 times since Sep 24, 2025, and over the history we have for it it has declined 8.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2987 per EA |
|---|---|
| All-time high | $0.3615 (Mar 11, 2026) |
| All-time low | $0.2987 (Sep 23, 2026) |
| 52-week high | $0.3615 |
| 52-week low | $0.2987 |
| Median price | $0.3408 |
| Average price | $0.3361 |
| Largest weekly change | +7.2% (Dec 17, 2025) |
| Weeks tracked | 54 |
| Tracking since | Sep 24, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine and Olmesartan Medoxomil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-OLMESARTAN 10-40 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-OLMESARTAN 10-40 MG, manufactured by Camber Pharmaceuticals Inc., is $0.2987 per EA (NDC 31722044830), effective Sep 30, 2026.
How has the price of AMLODIPINE-OLMESARTAN 10-40 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-OLMESARTAN 10-40 MG has declined 8.5%. It has been tracked across 54 weekly CMS publications since Sep 24, 2025.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-OLMESARTAN 10-40 MG?
Since Sep 24, 2025, the NADAC for AMLODIPINE-OLMESARTAN 10-40 MG has ranged from a low of $0.2987 (Sep 23, 2026) to a high of $0.3615 (Mar 11, 2026), with a median of $0.3408 per EA.
Are there cheaper alternatives to AMLODIPINE-OLMESARTAN 10-40 MG?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AMLODIPINE-OLMESARTAN 10-40 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures AMLODIPINE-OLMESARTAN 10-40 MG?
AMLODIPINE-OLMESARTAN 10-40 MG (NDC 31722044830) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.